Market Overview

Health Canada Approves Forest Labs' BYSTOLIC for Hypertension

Related FRX
Activis Shares Languish Post-Forest Deal
Among A Raft Of Index Changes, Affiliated Managers Group To Join S&P 500

Forest Laboratories, Inc. (NYSE: FRX) announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC® (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.

“We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important milestone for Forest, as it is the first product approved for our newly established Canadian subsidiary. We look forward to bringing additional innovative Forest products to the Canadian market,” commented David Solomon, Senior Vice President of Corporate Development and Strategic Planning, Forest Laboratories, Inc.

BYSTOLIC is expected to be available to Canadian patients in Q2 2013.

Forest Laboratories Canada Inc. operations are based in Toronto, Ontario. To learn more, visit

Posted-In: News


Related Articles (FRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters